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Background: Insulin resistance (IR) correlates closely with cardiovascular disease. C1q/TNF-related protein-3 (CTRP3)
is a novel adipokine that modulates insulin activity in various diseases. This study investigated the relationship between
CTRP3 and IR as well as systemic inflammation in newly diagnosed obese and hypertensive patients (NCT02226471).
Methods: Serum CTRP3 levels, anthropometric, inflammatory and metabolic parameters were measured in 180 obesity
and essential hypertensive patients and in 66 normal weight, normotensive subjects.
Results: The serum CTRP3 levels in the obesity group were lower than those in the NW group; these levels were also
lower in hypertensive subjects than in normotensive subjects. After adjusting for gender, systolic blood pressure (SBP) and
diastolic blood pressure (DBP), a modestly linear relationship was observed between CTRP3 and waist circumference (WC)
(r = -0.168, p = 0.009), waist-to-hip ratio (WHR) (r = -0.183, p = 0.004), homeostasis model assessment of IR (HOMA-IR)
(r = -0.264, p = 0.000), triglycerides (TG) (r = -0.136, p = 0.034), fasting blood glucose (FBG) (r = -0.155, p = 0.016), fasting
insulin (FINS) (r = -0.248, p = 0.000) and homeostasis model assessment of β-cell insulin secretion (HOMA-β) (r = -0.128,
p = 0.047). Multiple stepwise regression analysis revealed that gender, DBP and HOMA-IR were independently associated
with serum CTRP3 levels.
Conclusion: CTRP3 was an independent factor affecting blood pressure and IR, and may play an important role in the
pathogenesis of obesity and hypertension.
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Obesity has become a major global health problem, and
the proportion of adults with overweight or obesity has in-
creased substantially in the past thirty years [1]. Obesity is
considered one of the most important risk factors of car-
diovascular disease [2]. Previous research has indicated that
more than two-thirds of diagnosed hypertension can be
directly attributed to obesity [3]. Recent studies have
demonstrated that adipokines play important roles in the
pathogenesis of obesity and function as a link between* Correspondence: dwq_cq@126.com
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such as adiponectin, resistin, retinol-binding protein 4
(RBP4), are secreted by adipose tissues, which may play
a critical role in systemic inflammation and insulin re-
sistance (IR) in obesity and hypertension. However, the
precise roles of adipokines in regulation of IR require
further investigation.
Recently, a new and highly conserved family of se-
creted proteins, C1q/tumour necrosis factor-related
proteins (CTRPs), which includes fifteen family mem-
bers, was shown to possess structural homologies to
adiponectin. In addition, some CTRP members mani-
fest the metabolic regulatory function of adiponectin.
C1q/TNF-related protein-3 (CTRP3), a member of thehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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adipokine that inhibits the inflammation induced by lipo-
polysaccharide, Toll-like receptor 4 and fatty acid [5] and
induces adiponectin and resistin release in murine adipo-
cytes [6]. Adiponectin is the most well-characterised mem-
ber of the CTRP family, is tightly linked to IR and insulin
sensitivity, and is an important biomarker and therapeutic
target in obesity-associated metabolic diseases. To date,
several CTRPs have been shown to induce insulin-
sensitising effects similar to adiponectin [7]. Therefore,
these proteins, such as CTRP3, might compensate for a de-
ficiency of adiponectin, thereby providing an explanation
for why adiponectin knockout mice display only mild meta-
bolic disturbances, even when fed a high-fat diet [8].
To date, no data have been reported concerning the
relationship between CTRP3 and drug-naive, newly di-
agnosed obesity and hypertension subjects. Therefore,
we investigated the associations of CTRP3 and RBP4




We consecutively selected 826 Chinese subjects from the
general population who had undergone medical check-
ups at the Southwest Hospital Medical Center at the Third
Military Medical University from March to November
2013. After excluding 580 of the 826 subjects, a total of
246 subjects were enrolled in our study. The first group
enrolled 124 normal weight (NW) subjects. Their body
weight status was confirmed by body mass index (BMI).
The second group included 122 obesity subjects. All
subjects were newly diagnosed and had not received
any medical treatment. Obesity was defined according
to the WHO Western Pacific Regional Office definition
[9]. Based on blood pressure measurements, the subjects
were divided into four subgroups: NW-normal blood
pressure subgroup (NW-NBP), NW-hypertension sub-
group (NW-HTN), obesity-normal blood pressure sub-
group (OB-NBP), and obesity-hypertension subgroup
(OB-HTN). The diagnosis of hypertension was based
on the World Health Organization criteria [10].
The subjects exhibited stable body weight for at least
3 months prior to testing. The subjects enrolled in the
analysis met the following inclusion criteria: (1) 20 years
of age or older and younger than 65 years old; (2) essen-
tial hypertension; (3) obesity; and exclusion criteria: (1)
fasting blood glucose (FBG) > 6.1 mmol/L and diabetes or
thyroid disease; (2) taking antihypertensive, antidiabetic or
lipid-lowering medications; (3) clinical symptoms or signs
of infection; (4) liver, kidney, heart disorders or other
critical diseases, such as fractures, osteoporosis or tu-
mours; (5) target organ damage; (6) pregnant or lactat-
ing. The study was approved by the Human ResearchEthics Committee at Southwest Hospital, and informed
consent was obtained from all patients and controls.
Anthropometric measurements and definitions
All participants were required to fast overnight (8-10 h)
before the physical examination. Medical histories, an-
thropometric parameters were recorded followed by blood
pressure measurements. Blood pressure was measured
three times in 2 min intervals on the upper arm using a
mercury sphygmomanometer (YuYue Medical Equipment
& Supply CO., LTD., Jiangsu Province, China), with the
subject in a seated, resting position after 10 minutes of
rest; the mean of the three measurements was used for
the statistical analysis. Anthropometric parameters, in-
cluding weight, height and hip and waist circumference
(WC), were measured using the International Collabora-
tive Study on Hypertension in Blacks (ICSHIB) standar-
dised protocol [11]. BMI was calculated as body weight in
kilograms divided by the square of the height (m2). The
waist-to-hip ratio (WHR) was calculated as the waist-to-
hip circumference.
We defined current alcohol consumption as more than
1 drink of any type per month, and not currently drinking
as less than 1 drink of any type per month [12]. Smokers
were defined as having smoked more than 100 cigarettes
in a lifetime and having smoked at least one cigarette daily
for 6 months by the time of the interview [13]. Obesity
was defined as a BMI ≥ 25 kg/m2, as suggested by the
WHO Western Pacific Regional Office [9]. Hypertension
was defined as a systolic blood pressure (SBP) ≥ 140 mmHg
and/or a diastolic blood pressure (DBP) ≥ 90 mmHg [10].
Experimental procedures and serum samples
Overnight fasting blood samples were collected in tubes
containing liquid EDTA; the samples were centrifuged at
-4°C and maintained at -80°C until assayed. A certified
laboratory procedure was used to evaluate the metabolic
parameters, including fasting blood glucose (FBG), blood
uric acid (UA), total cholesterol (TC), triglycerides (TG),
low-density lipoprotein C (LDL-C), high-density lipoprotein
C (HDL-C) and fasting insulin (FINS). FBG was assayed
using the glucose oxidase method. UA, TC, TG, LDL-C
and HDL-C concentrations were determined enzymatically.
The white blood cell (WBC) count was measured using the
Serono-Baker System 9000 Hematology Analyzer (Serono-
Baker Diagnostics, Allentown, Pennsylvania).
Serum CTRP3 levels were determined by enzyme-
linked immunosorbent assay (human CTRP3 ELISA kit,
Aviscera Bioscience, Inc., Santa Clara, CA, USA). The
intra-assay coefficients of CTRP3 were 4-6%, and the
inter-assay coefficients were 8-10%. The linear ranges of
the assays were 15.6 to 1000 ng/ml for CTRP3. Serum
RBP4 levels were evaluated using a commercially available
ELISA kit (R&D Systems, Inc., Minneapolis, MN, USA).
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and the interassay coefficients were less than 15%. The lin-
ear ranges of the assays were 1.0 to 300 μg/ml for RBP4.
The homeostasis model assessment of IR (HOMA-IR) as
an indicator of IR and the homeostasis model assessment
of β-cell insulin secretion (HOMA-β) were calculated from
the FINS and FBG levels using the following equations:
HOMA-IR = FINS (μU/ml) × FBG (mmol/l)/22.5; and
HOMA-β = 20 × FINS (μU/ml) / FBG (mmol/l) - 3.5 [14].
Statistical analysis
The experimental data were analysed using SPSS software
(SPSS, Chicago, IL, USA), version 17.0. Continuous vari-
ables are presented as the means ± standard deviations,
and categorical variables are presented as absolute and
relative frequencies (%). Before the statistical analysis, theTable 1 Clinical characteristics of the study subjects
Factor NW
NW-NBP NW-HTN
Age (year) 49.21 ± 8.95 49.90 ± 8.6
Gender (M/F)# 66(43/23) 67(48/19)
BMI (kg/m2) 22.50 ± 1.45 22.10 ± 1.6
WC (cm) 79.88 ± 6.51 81.36 ± 7.0
WHR 0.87 ± 0.05 0.89 ± 0.05
SBP (mmHg) 119.26 ± 9.44 154.76 ± 1
DBP (mmHg) 75.89 ± 6.61 100.07 ± 7
UA (μmol/l) 295.10 ± 72.89 332.22 ± 7
TG (mmol/l) 1.39 ± 0.60 2.05 ± 1.15
TC (mmol/l) 4.97 ± 0.92 5.38 ± 0.94
LDL-C (mmol/l) 2.70 ± 0.59 2.74 ± 0.58
HDL-C (mmol/l) 1.58 ± 0.40 1.41 ± 0.25
FBG (mmol/l) 5.38 ± 0.52 5.29 ± 0.54
FINS (pmol/l) 9.54 ± 3.23 10.93 ± 3.0
WBC (109 cells/l) 5.25 ± 1.07 6.06 ± 1.17
RBP4(μg /ml) 50.97 ± 15.19 65.09 ± 17
HOMA-IR 2.29 ± 0.85 2.60 ± 0.90
HOMA-β 109.83 ± 51.11 130.62 ± 4
Smoking (%)# 32.8 37.0
Drinking (%)# 26.6 34.7
Data represent the means ± SD or frequency (percentage).
CTRP3, TG, FINS, HOMA-IR and HOMA-β were log-transformed prior to analysis.
#chi-squared test.
ap < 0.01 compared with NW-NBP.
bp < 0.01 compared with NW-HTN.
cp < 0.01 compared with OB-NBP.
NW, normal weight subject; OB, obese subject; NW-NBP, NW with normal blood pre
NW-HTN, NW with hypertension; OB-NBP, OB with normal blood pressure; OB-HTN,
BMI, body mass index; WC, waist circumference; WHR, waist-to-hip ratio.
SBP, systolic blood pressure; DBP, diastolic blood pressure.
UA, uric acid; TG, triglyceride; TC, total cholesterol.
LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein choleste
FBG, fasting blood glucose; FINS, fasting plasma insulin; WBC,white blood cell.
HOMA-IR, HOMA-IR index; HOMA-β, HOMA β cell function index.data were subjected to a normal distribution analysis using
the Kolmogorov-Smirnov test. Non-normally distributed
data (CTRP3, TG, FINS, HOMA-IR and HOMA-β) were
converted by logarithmic transformation. Categorical vari-
ables were compared using the chi-squared test. The
Student’s t-test and analysis of variance (ANOVA) were
used to compare groups. In addition, a post-hoc least-
significant difference (LSD) test was used for equal vari-
ances of assumed variables, and Dunnett's test was used
for equal variances of variables that were not assumed.
Interrelationships between variables were analysed with
Pearson’s correlation analysis. Partial correlation ana-
lysis was performed to control for gender and blood
preesure. Multiple regression analysis was performed
using stepwise linear regression to correct the effects of
the covariates and to test the independent factors, andOB
OB-NBP OB-HTN
3 49.28 ± 8.73 48.16 ± 7.87
58(35/23) 55(37/18)
5 28.02 ± 1.65ab 28.52 ± 2.00ab
2 91.80 ± 7.29ab 95.79 ± 5.76abc
a 0.91 ± 0.06a 0.95 ± 0.05abc
1.39a 125.97 ± 10.09ab 159.89 ± 14.54ac
.51a 77.97 ± 7.07b 101.65 ± 11.46ac
8.21a 346.61 ± 68.96a 387.85 ± 99.98ab
a 2.05 ± 1.48a 2.41 ± 1.02abc
a 5.03 ± 0.82b 5.25 ± 0.83
2.80 ± 0.50 2.72 ± 0.49
1.34 ± 0.28a 1.33 ± 0.34a
5.60 ± 0.57ab 5.47 ± 0.47
7 14.47 ± 6.13ab 16.13 ± 5.19ab
a 5.90 ± 1.50a 6.05 ± 1.50a
.09a 49.76 ± 14.72b 64.08 ± 18.86ac
a 3.64 ± 1.71ab 3.93 ± 1.34ab










The clinical characteristics of the study subjects are pre-
sented in Table 1. There were no significant differences
among the four subgroups in terms of age, gender and
LDL-C distribution. The levels of WHR, SBP, DBP, UA,
TG, TC, WBC, HOMA-IR and HOMA-β were higher in
the NW-HTN subgroup than in the NW-NBP subgroup,
and the levels of WC, WHR, SBP, DBP, TG and HOMA-
β were higher in the OB-HTN subgroup than in the OB-
NBP subgroup. Compared with the NW-HTN subgroup,
the levels of BMI, WC, WHR, UA, TG, FINS, HOMA-
IR and HOMA-β were significantly increased in the OB-
HTN subgroup. The levels of BMI, WC, WHR, SBP, UA,
TG, HDL-C, FBG, FINS, WBC, HOMA-IR and HOMA-β
in the OB-NBP subgroup and the levels of BMI, WC,
WHR, SBP, DBP, UA, TG, HDL-C, FINS, WBC, HOMA-
IR and HOMA-β in the OB-HTN subgroup were signi-
ficantly increased compared with those in the NW-NBP
subgroup.
Serum CTRP3 and RBP4 levels
The serum CTRP3 levels in the obesity group were lower
than those in subjects with NW in both the NBP and
HTN groups (94.53 ± 43.94 vs 116.84 ± 52.10 ng/ml, p <
0.001). Compared with the NW-NBP group, the serum
CTRP3 levels were significantly decreased in the OB-NBP
group (136.29 ± 41.86 vs 93.11 ± 40.26 ng/ml, p < 0.001).
Compared with NW-NBP group, the serum CTRP3 levels
were significantly decreased in the NW-HTN group
(136.29 ± 41.86 vs 94.71 ± 54.05 ng/ml, p < 0.001) (Figure 1A).
The CTRP3 concentration was significantly higher in
women than in men (121.94 ± 52.23 vs 97.54 ± 45.92 ng/ml,
p < 0.001) (Figure 1B).Figure 1 The serum CTRP3 levels in different subgroups. A - Comparis
levels in men and women.There were no differences between the serum RBP4
levels in the normal weight and obesity subjects (57.58 ±
17.53 vs 56.22 ± 18.11 μg /ml, p = 0.550). Compared with
the NW-NBP group, the RBP4 serum levels were signifi-
cantly elevated in the NW-HTN group (50.97 ± 15.19 vs
65.09 ± 17.09 μg /ml, p < 0.001).Relationships between serum CTRP3 levels and metabolic,
inflammatory as well as IR parameters
Bivariate correlation analysis indicated that serum CTRP3
concentrations were negatively correlated with body fat
parameters, according to BMI (r = -0.199, p = 0.002)
(Figure 2A), WC (r = -0.299, p = 0.000), WHR (r = -0.320,
p = 0.000), HOMA-IR (r = -0.316, p = 0.000) (Figure 2B),
as well as SBP (r = -0.251, p = 0.000) (Figure 2C), DBP
(r = -0.288, p = 0.000) (Figure 2D), UA (r = -0.174, p = 0.006),
TG (r = -0.241, p = 0.000), FBG (r = -0.137, p = 0.032), FINS
(r = -0.308, p = 0.000), WBC (r = -0.170, p = 0.009), HOMA-
β (r = -0.153, p = 0.003) and drinking (r = -0.150, p = 0.037).
After adjusting for gender, SBP and DBP, the correlation
remained between CTRP3 and WC (r = -0.168, p = 0.009),
WHR (r = -0.183, p = 0.004), HOMA-IR (r = -0.264,
p = 0.000), TG (r = -0.136, p = 0.034), FBG (r = -0.155,
p = 0.016), FINS (r = -0.248, p = 0.000) and HOMA-β
(r = -0.128, p = 0.047). After adjusting for gender, age and
BMI, the correlation remained between CTRP3 and WC
(r = -0.159, p = 0.013), WHR (r = -0.200, p = 0.002), HOMA-
IR (r = -0.257, p = 0.000), TG (r = -0.168, p = 0.009), SBP
(r = -0.296, p = 0.000), DBP (r = -0.288, p = 0.000), WBC
(r = -0.152, p = 0.021), FINS (r = -0.250, p = 0.000) and
HOMA-β (r = -0.140, p = 0.029). Multiple stepwise regres-
sion analysis revealed that gender, DBP and HOMA-IR
were independently related to the CTRP3 levels (β=
0.159, -0.252, -0.240, all p < 0.05). The following multiple re-
gression equation was used: Y CTRP3 = 5.425 - 0.009XDBP -
0.303X HOMA-IR + 0.164XGender) (Table 2).on of the CTRP3 levels among the four subgroups. B - The serum CTRP3
Figure 2 Correlation between CTRP3 and BMI (A), HOMA-IR (B), SBP (C) or DBP (D).
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Adipose tissue secretes a variety of adipokines that play
major roles in regulating glycolipid metabolism and sys-
temic inflammation by directly or indirectly affecting in-
sulin sensitivity and resistance [15]. CTRP3, a secreted
protein, was cloned by Maeda et al. [16], first investi-
gated in human plasma and reported by Wurm et al.
[17]. Of the CTRPs studied thus far, CTRP3 is the clos-
est functional homolog of adiponectin and the most
promising candidate to play a role in inflammation and
metabolism [7]. Compared with other adipokines, less
information is known about CTRP3 in metabolic syn-
drome, systemic inflammation and IR, although the re-
sults of previous studies have been conflicting [18-21].
Therefore, it is worth exploring the clinical characteris-
tics of CTRP3 in obesity and hypertension.
CTRP3 mRNA expression is strongly induced during
adipocyte differentiation, and the knockdown of CTRP3
in preadipocytes leads to dedifferentiation into a more
proinflammatory and immature phenotype [5]. Immuno-
blot analysis suggests that CTRP3 mRNA levels in fat
tissue and protein levels in serum are similar in variousmice models [22]. Circulating CTRP3 levels increase
with fasting, are decreased in high-fat-diet-induced
obese mice with high leptin levels, and are increased in
leptin-deficient ob/ob mice [23]. CTRP3 may play an
important role in progress of obesity through regulating
energy metabolism, but mechanism should be further
investigated. CTRP3 levels in metabolic syndrome and car-
diovascular disease were puzzling in previous clinical stud-
ies. Recently, Tan et al. reported that serum and omental
adipose tissue CTRP3 were significantly lower in women
with polycistic ovary syndrome compared with control sub-
jects, and a negative association was observed with BMI,
WHR, glucose, insulin, and triglycerides, which is consist-
ent with our results [20]. However, another research team
reported that subjects with metabolic syndrome had signifi-
cantly higher CTRP3 levels compared with subjects without
metabolic syndrome; they also observed significant positive
associations between plasma CTRP3 levels and cardiometa-
bolic risk factors [18], inconsistent with Ban et al’s report
recently [24]. A variety of reasons possibly were involved,
such as ethnicity, medication and so on, in our study we ex-
cluded related confounding factors in order to reduce
Table 2 Linear and multiple regression analysis of the anthropometric and metabolic parameters associated with
CTRP3 levels in the subjects
Univariate correlations Multivariate regression analysis
Variable r p-value β p-value
Gender _ _ 0.159 0.026
BMI (kg/m2) -0.199 0.002 _ _
WC (cm) -0.299 0.000 _ _
WHR -0.320 0.000 _ _
SBP (mmHg) -0.251 0.000 _ _
DBP (mmHg) -0.288 0.000 -0.252 0.001
UA (μmol/L) -0.174 0.006 _ _
TG (mmol/l) -0.241 0.000 _ _
TC (mmol/l) -0.111 0.081 _ _
LDL-C mmol/l) -0.088 0.200 _ _
HDL-C (mmol/l) 0.125 0.068 _ _
FBG (mmol/l) -0.137 0.032 _ _
FINS (pmol/l) -0.308 0.000 _ _
WBC (109 cells/l) -0.170 0.009
HOMA-IR -0.316 0.000 -0.240 0.001
HOMA-β -0.189 0.003 _ _
Smoking -0.130 0.070 _ _
Drinking -0.150 0.037 _ _
RBP4 0.065 0.313 _ _
CTRP3, TG, FINS, HOMA-IR and HOMA-β were log-transformed prior to analysis.
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subsequently reported that CTRP3 levels were not signifi-
cantly different in participants with and without obesity
and that a 3-month combined exercise program signifi-
cantly decreased CTRP3 levels in obese Korean women
[19]. Interestingly, in another study, the same authors re-
ported that serum CTRP3 was not significantly lower in
subjects with metabolic syndrome compared with controls
and that serum CTRP3 was significantly negatively associ-
ated with WC, DBP, serum glucose and triglycerides [21].
As we know, metabolic syndrome is composed of diverse
components, including overweight or obesity, hypergly-
cemia, hypertension and dyslipidemia. We investigated the
relationship between CTRP3 and individual component of
metabolic syndrome, such as obesity and hypertension in
order to understand more detailed each other after ex-
cluding other confounding factors. In the current study, we
detected serum CTRP3 concentrations in humans and in-
vestigated the relationships between serum CTRP3 levels
and relevant factors. The present data suggested that the
CTRP3 concentrations were significantly decreased in pa-
tients with obesity or hypertension compared to control
subjects. Moreover, a correlation analysis demonstrated
that serum CTRP3 was significantly negatively associated
with obese, inflammtionary and IR parameters as well as
blood pressure levels. Multiple regression analysis revealedthat only gender, DBP and HOMA-IR were predictive of
serum CTRP3 levels. Serum RBP4 was considered as an
inflammatory adipokine in early study, subsequent other
research results were inconsistent, no significantly rela-
tionship was observed between RBP4 and CTRP3 in this
study. Circulating RBP4 levels were not significantly differ-
ent between obese patients and normal weight subjects
but were significantly elevated in hypertensive patients
compared with normotensive subjects, consistent with
our previous study [25], which revealed that RBP4 possibly
involved in pathogenesis of hypertension, not obesity.
Considering that adipokine expression may be affected
by sex hormones, we compared serum CTRP3 concen-
trations in males and females, and the results showed
that CTRP3 concentrations were significantly higher in
women than in men. These sex-specific differences in
CTRP3 levels were similar for adiponectin and other
adipokines. The results of the current study are similar
to a previous report [19]. Separately observating differ-
ent genders, TG and HOMA-IR negatively influenced
CTRP3 levels in both men and women subjectives, but
the relation of FBG and FINS only was in women. Sex
hormones may influence CTRP3 expression, it has been
evidenced that androgen, oestrogen and adiponectin can
regulate adiponectin receptors. CTRP3 was lower in sex
hormones imbanlance women with polycystic ovary
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vealed that serum CTRP3 levels vary significantly accord-
ing to the sex and genetic backgrounds of the mice [22].
Recent study indicates that CTRP3 is a potent anti-
inflammatory adipokine that inhibits proinflammatory
pathways. Ablation of CTRP3 by small interfering RNA
increases the expression of proinflammatory adipokines
including C-C motif chemokine ligand-2(CCL2) and
decreases adiponectin expression in preadipocytes [5].
The WBC count is a widely available and broadly used
marker of systemic inflammation. The present study re-
vealed that CTRP3 levels were negative correlation with
WBC in obese and hypertensive subjects. However, the
relationship was vanished after adjusting for confound-
ing fator of hypertension. The result indicated CTRP3
influences systemic inflammation possibly mainly in
hypertensive, not obese subjects. The WBC count has
been considered as a marker of cardiovascular disease
risk measured through indicators of atherosclerosis and
arterial stiffness in previous data [26].
CTRP3 mRNA was one of the most strongly up-regulated
transcripts in rat carotid arteries after balloon injury [27]. In
adult male mice, myocardial infarction significantly inhibits
adipocyte CTRP3 expression and reduces plasma CTRP3
levels, and CTRP3 replenishment improves the survival rate,
restores cardiac function, attenuates cardiomyocyte apop-
tosis, increases revascularisation, and dramatically reduces
interstitial fibrosis, and the protective effect of adipocyte-
conditioned medium against hypoxia-induced cardiomyo-
cyte injury is significantly blunted when CTRP3 is knocked
down [28]. A clinical study has suggested that coronary ar-
tery disease or stable angina pectoris patients have signifi-
cantly lower circulating CTRP3 concentrations compared
with control subjects, which suggests that CTRP3 may be
useful in assessing the risk of coronary artery disease [29]. In
the current study, serum CTRP3 was decreased and nega-
tively correlated with blood pressure in hypertensive
subjects, and one of independent predictor was DBP. Based
on the above literature and results, CTRP3 as an anti-
inflammatory cytokines has a cardioprotective effect through
inhibiting production of pro-inflammatory cytokines, che-
mokines and so on. However, further mechanism is needed
to clarify. In short, CTRP3 is a novel antiapoptotic, proan-
giogenic, and cardioprotective adipokine that may play an
important role in directing vascular smooth muscle cell
proliferation in the pathophysiology of neointimal hyper-
plasia and restenosis following angioplasty [30].
Adipokines can influence insulin sensitivity, and the
regulation of adipokines may play a pivotal role in the
aetiology of IR, which is associated with obesity and car-
diovascular disease. Therefore, CTRP3 might also exert
profound effects on local insulin sensitivity within adipose
tissue. In this context, the present results the first time
suggest that CTRP3 may indicate insulin sensitivity andplays an important and compensatory role in increasing
insulin sensitivity and improving glycolipid metabolism.
CTRP3 can sufficiently lower glucose levels and reduce
glucose output in normal and insulin-resistant ob/ob mice
by activating the Akt signalling pathway in the liver and
suppressing the hepatic gluconeogenic gene and enzyme
expression [23]. Similarly, Shike et al. described an associ-
ation between fasting glucose levels and the centromeric
region on chromosome 15 near D15Mit225, with a max-
imum score obtained in the region containing the CORS-
26 gene [31].Conclusions
To the best of our knowledge, this study is the first to show
that circulating CTRP3 levels are drastically decreased in
naive, newly diagnosed obese and hypertensive patients.
CTRP3, as an adipokine, was closely associated with IR, gly-
colipid metabolism and gender. Therefore, it may play a
substantial pathophysiological role in the mechanism of
obesity and hypertension. However, some study limitations
must be considered. First, the study subjects consisted of a
small number of men and women of Chinese ethnicity;
hence, the generalisability of our study to other ethnici-
ties is unknown. Second, this cross-sectional analysis
restricts our ability to draw causal conclusions. Third,
we did not perform oral glucose tolerance tests or glucose
clamp studies to determine insulin resistance because of
condition limitations. We observed close relationships be-
tween CTRP3 and IR, hypertension as well as sysmetic
chronic inflammation, but the molecular mechanisms be-
tween these relationships require validation in future studies.Competing interests
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